Page 83 - Read Online

Page 18 of 18 Lee et al. Hepatoma Res 2018;4:51 I http://dx.doi.org/10.20517/2394-5079.2018.78

membrane-bound TGF-beta 1. J Immunol 2009;182:240-9.
86. Yan W, Liu X, Ma H, Zhang H, Song X, Gao L, Liang X, Ma C. Tim-3 fosters HCC development by enhancing TGF-beta-mediated
alternative activation of macrophages. Gut 2015;64:1593-604.
87. Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, Liu J, Shi L, Liu C, Wang G, Zou W. Tim-3/galectin-9 signaling pathway mediates
T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology
2012;56:1342-51.
88. Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, Popovic A, Pawlik TM, Kim AK, Zhu Q, Jaffee EM, Taube JM, Anders RA.
Characterization of the immune microenvironment in hepatocellular carcinoma. Clin Cancer Res 2017;23:7333-9.
89. Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y, Shimosegawa T. Expression of galectin-3 involved in prognosis of patients with
hepatocellular carcinoma. Hepatol Res 2008;38:1098-111.
90. Li FJ, Zhang Y, Jin GX, Yao L, Wu DQ. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+)
T cell in HCC patients. Immunol Lett 2013;150:116-22.
91. Hui Z, Zhang X, Ren B, Li R, Ren X. Rapid response of advanced squamous non-small cell lung cancer with thrombocytopenia after
first-line treatment with pembrolizumab plus autologous cytokine-induced killer cells. Front Immunol 2015;6:633.
92. Niu Q, Wang W, Li Y, Qin S, Wang Y, Wan G, Guan J, Zhu W. Cord blood-derived cytokine-induced killer cells biotherapy combined
with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol 2011;11:449-56.
93. Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C, Terunuma H, He H, Li W. Combination of radiofrequency ablation and sequential
cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer 2014;134:342-51.
94. Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu FM, He N, Pan CC, Xia JC, Wu PH, Zhao M. Cytokine-induced killer cells in
combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J
Immunother 2013;36:287-93.
95. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342:1432-3.
96. Clifford RJ, Zhang J, Meerzaman DM, Lyu MS, Hu Y, Cultraro CM, Finney RP, Kelley JM, Efroni S, Greenblum SI, Nguyen CV, Rowe
WL, Sharma S, Wu G, Yan C, Zhang H, Chung YH, Kim JA, Park NH, Song IH, Buetow KH. Genetic variations at loci involved in the
immune response are risk factors for hepatocellular carcinoma. Hepatology 2010;52:2034-43.